Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Rhythm Pharmaceuticals Inc. has 2 pending office actions located in the Biotechnology & Pharmaceuticals technology area. Despite having multiple active matters, the company's prosecution is centralized under a distinct examiner and a distinct art unit. This centralization suggests that the pending applications likely share closely related subject matter or fall within a very specific regulatory category.
The busiest examiner, LEE, JIA-HAI, is responsible for both of the 2 pending office actions. This means that the outcome of the company's current prosecution efforts rests entirely with this single examiner. A practitioner working on this portfolio can focus their efforts on understanding the specific preferences and prior art interpretations of this individual rather than navigating multiple examiner personalities. The examiner's history in the Biotechnology & Pharmaceuticals field will be a key factor in the prosecution.
Because all activity is confined to the distinct art unit, the company faces a uniform set of examination guidelines and internal policies. This lack of departmental diversity simplifies the administrative burden of tracking different office procedures. The 2 pending office actions represent the total current engagement with the USPTO for this portfolio, allowing for a concentrated and consistent legal strategy.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, JIA-HAI | 2 | 49.0% | +47.0% |
| CHANDRA, GYAN | 1 | 71.3% | +27.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18028117 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | CHANDRA, GYAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 15764730 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | LEE, JIA-HAI | 99d overdue |
| 17712752 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | LEE, JIA-HAI | 86d overdue |
| 18028117 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | CHANDRA, GYAN | — |
| Art Unit | Apps |
|---|---|
| 1658 | 2 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18028117 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | CHANDRA, GYAN | 1674 | §103§112 | Non-Final OA | — | Pending | Mar 23, 2023 |
| 17712752 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | LEE, JIA-HAI | 1658 | §103DP | Final Rejection | 86d overdue | Pending | Apr 04, 2022 |
| 15764730 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | LEE, JIA-HAI | 1658 | §103DP | Final Rejection | 99d overdue | Pending | Mar 29, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial